G 305

Drug Profile

G 305

Alternative Names: Cancer vaccine NY-ESO-1 - Immune Design; G-305; ID-G305; IDC-G305; NY-ESO-1/GLA-SE cancer vaccine - Immune Design

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Sarcoma

Most Recent Events

  • 10 Mar 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in European Union
  • 08 Jan 2016 G 305 receives Orphan Drug status for Soft tissue sarcoma in USA
  • 13 May 2015 Interim efficacy and adverse events data from a phase I trial in Cancer released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top